ArticleInternational ophthalmology2025
In vivo confocal microscopy (IVCM) analysis of corneal sub-basal nerve plexus (SNP) and corneal sensitivity after micropulse transscleral cyclophotocoagulation (MP-TSCPC) in glaucoma patients.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MicroPulse Transscleral Cyclophotocoagulation for Early to Moderate Glaucoma: A Case Series of 11 Eyes with One-Year Follow-Up and Literature Review.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the clinical outcome of micropulse transscleral cyclophotocoagulation (MP-TSCPC) and its effect on corneal sensitivity, as well as corneal nerve parameters using in vivo confocal microscope (IVCM) in eyes with glaucoma. PATIENTS AND
methodsThis was a prospective longitudinal study recruiting consecutive glaucoma patients who were scheduled to undergo MP-TSCPC for intraocular pressure (IOP) control in a tertiary center. Pre-operative and postoperative clinical parameters were compared including best-corrected visual acuity, IOP, number of topical glaucoma medication, requirement of oral acetazolamide and corneal sensitivity. Intraoperative and postoperative complications were recorded. Pre-operative and postoperative corneal nerve parameters measured using IVCM were analysed in both operated and non-operated eye. All clinical and imaging parameters were compared longitudinally between baseline, postoperative 2 weeks and 1 month.
resultsTwenty consecutive glaucoma patients who received MP-TSCPC between January 2024 and May 2024 were recruited. Postoperatively, there was a significant reduction in IOP (p = 0.000) and oral acetazolamide use (p = 0.001) while visual acuity were maintained (p = 0.710). However, there were reduced corneal sensitivity (p = 0.014), decrease in corneal nerve fibre density (CNFD) (p = 0.017) and corneal nerve branch density (CNBD) (p = 0.047) as detected by IVCM from baseline to 1 month in the operated eye.
conclusionMP-TSCPC is an effective glaucoma treatment in terms of IOP control and reduction of glaucoma medications. However, it may potentially result in reduced corneal sensitivity, corneal nerve fiber density and branch density at postoperative 1 month.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.